Our Services

Breast Cancer

In the U.S., breast cancer is the second most common cancer in women after skin cancer. It can occur in both men and women. The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Breast cancer can also begin in the cells of the lobules and in other tissues in the breast. Invasive breast cancer is breast cancer that has spread from where it began in the ducts or lobules to surrounding tissue.

A Phase I/IIa Study of the Whole-Cell Vaccine BriaVax in Metastatic or Locally Recurrent Breast Cancer Patients

  • All patients will receive treatment with BriaVax, Cytoxan, and Interferon
  • Patients need to have completed at least one prior treatment
  • Main study doctor (principal investigator): Ian Anderson, MD
  • For more information, please contact the coordinator, Sabine Ucik, at 707-521-3830 or at Sabine.Ucik@stjoe.org

Novel Vaccine, NeuVax, Plus Herceptin for HER2 Positve (3+) Breast Cancer Patients Clinical Trial

  • Stage I-III breast cancer
  • All patients receive treatment with herceptin alone or herceptin plus the vaccine
  • Patients must be high risk:
  • Main study doctor (principal investigator): Jarrod Holmes,MD
  • For more information, please contact the lead coordinator, Jennafer Carlin Rosset, at 707-521-3833 or at Jennafer.Carlin@stjoe.org

Novel Vaccine, NeuVax, Plus Herceptin for HER2 Negative (1+ or 2+) Breast Cancer Patients Clinical Trial

  • Stage I-III breast cancer
  • All patients receive treatment with herceptin alone or herceptin plus the vaccine
  • Patients must be clinically cancer-free after standard treatment
  • Main study doctor (principal investigator): Jarrod Holmes,MD
  • For more information, please contact the lead coordinator, Jennafer Carlin Rosset, at 707-521-3833 or at Jennafer.Carlin@stjoe.org

A Registry Study to Better Understand Ibrance (Palbociclib) in Hormone Receptor Positive Advanced Breast Cancer

  • For advanced breast cancer
  • Patients must be hormone receptor positive and be cleared to begin treatment with Ibrance (palbociclib), but not have started, prior to enrolling in the study
  • Patients complete questionnaires to help physicians better understand Ibrance in the real-world setting
  • There is no treatment involved with this study
  • Main study doctor (principal investigator): Thomas Stanton, MD
  • For more information, please contact the coordinator, Sabine Ucik, at 707-521-3830 or at Sabine.Ucik@stjoe.org